These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4565369)

  • 21. Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure.
    Henderson SJ; Xia J; Wu H; Stafford AR; Leslie BA; Fredenburgh JC; Weitz DA; Weitz JI
    Thromb Haemost; 2016 Mar; 115(3):533-42. PubMed ID: 26489782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an in vitro fibrin clot model to evaluate fibrinolytic agents for wound care application.
    Viennet C; Laurensou C; Goydadin AC; Faivre B; Muret P; Humbert P
    J Wound Care; 2014 Feb; 23(2):66-7, 70, 72. PubMed ID: 24526082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epsilon-(gamma-glutamyl) lysine cross-links: determination in fibrin from normal and factor XIII-deficient individuals.
    Pisano JJ; Bronzert TJ; Peyton MP; Finlayson JS
    Ann N Y Acad Sci; 1972 Dec; 202():98-113. PubMed ID: 4629559
    [No Abstract]   [Full Text] [Related]  

  • 24. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
    von dem Borne PA; Cox LM; Bouma BN
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STUDIES ON THE RELATIONSHIP BETWEEN FIBRIN-STABILIZING FACTOR, CALCIUM AND INHIBITION OF FIBRINOLYSIS.
    TYLER HM; LACK CH
    Clin Sci; 1965 Jun; 28():527-36. PubMed ID: 14316258
    [No Abstract]   [Full Text] [Related]  

  • 26. Fibrinogen and factor XIII at the intersection of coagulation, fibrinolysis and inflammation.
    Hoppe B
    Thromb Haemost; 2014 Oct; 112(4):649-58. PubMed ID: 25182841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effects of divalent cations on the fibrin clot formation and its lysis].
    Subbotina TF; Galebskaia LV; Shcherbak IG
    Biomed Khim; 2005; 51(1):60-5. PubMed ID: 15850220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors.
    Lenfors S; Gustafsson D
    Semin Thromb Hemost; 1996; 22(4):335-42. PubMed ID: 8944418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen.
    Shen L; Lorand L
    J Clin Invest; 1983 May; 71(5):1336-41. PubMed ID: 6853717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
    Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro potentiation of urokinase-activated lysis of human fibrin clots.
    Singh K; Vézina C
    J Med; 1974; 5(6):297-302. PubMed ID: 4528600
    [No Abstract]   [Full Text] [Related]  

  • 32. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin.
    Siebenlist KR; Meh DA; Mosesson MW
    Thromb Haemost; 2001 Nov; 86(5):1221-8. PubMed ID: 11816711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of phosphatidylserine on formation and lysis of fibrin].
    Byshevskiĭ ASh; Lapusova TM; Mukhacheva IA
    Vopr Med Khim; 1978; 24(4):510-4. PubMed ID: 150701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
    Jansen JW; Haverkate F; Koopman J; Nieuwenhuis HK; Kluft C; Boschman TA
    Thromb Haemost; 1987 Apr; 57(2):171-5. PubMed ID: 2440124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro effects of detergent sclerosants on clot formation and fibrinolysis.
    Parsi K; Exner T; Low J; Fung Ma DD; Joseph JE
    Eur J Vasc Endovasc Surg; 2011 Feb; 41(2):267-77. PubMed ID: 21183368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.
    Marsh JN; Senpan A; Hu G; Scott MJ; Gaffney PJ; Wickline SA; Lanza GM
    Nanomedicine (Lond); 2007 Aug; 2(4):533-43. PubMed ID: 17716136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The activation of plasma factor XIII with the snake venom enzymes ancrod and batroxobin marajoensis.
    Walter M; Nyman D; Krajnc V; Duckert F
    Thromb Haemost; 1977 Aug; 38(2):438-46. PubMed ID: 579487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The in vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia.
    Shenkman B; Livnat T; Misgav M; Budnik I; Einav Y; Martinowitz U
    Platelets; 2012; 23(8):604-10. PubMed ID: 22273510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Our ancient heritage in blood clotting and some of its consequences.
    Laki K
    Ann N Y Acad Sci; 1972 Dec; 202():297-307. PubMed ID: 4508929
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.